12 products were found matching your search for Market Capitalization in 1 shops:

A theoretical and practical guide that enables readers to make sound investment and financing decisions This book is a technical finance book that surveys the private capital markets-the major uncharted financial market. Representing nearly half of the U.S. gross national product, these markets are largely ignored, partially because of the difficulty obtaining information and because of the lack of a unified structure to approach them. This book provides a structured framework that owner-managers and their professional advisors can use to effectively deal with the complicated issues of valuation and capital structure and transfer issues. Robert T. Slee, CBA, CPIM (Charlotte, NC), is President of Robertson Foley, an investment banking firm providing corporate finance service to private companies.

A theoretical and practical guide that enables readers to make sound investment and financing decisions This book is a technical finance book that surveys the private capital markets-the major uncharted financial market. Representing nearly half of the U.S. gross national product, these markets are largely ignored, partially because of the difficulty obtaining information and because of the lack of a unified structure to approach them. This book provides a structured framework that owner-managers and their professional advisors can use to effectively deal with the complicated issues of valuation and capital structure and transfer issues. Robert T. Slee, CBA, CPIM (Charlotte, NC), is President of Robertson Foley, an investment banking firm providing corporate finance service to private companies.

Buy with confidence! Book is in new, never-used condition 3.88

Connecting readers with great books since 1972! Used textbooks may not include companion materials such as access codes, etc. May have some wear or writing/highlighting. We ship orders daily and Customer Service is our top priority!

The recent changes in equity, derivatives and commodity exchanges are opening opportunities for exchanges, investment banks and capital markets generally. Despite the market capitalization of companies listed on exchanges running into trillions of dollars worldwide, there is no mainstream book using extensive research to address the major issues facing the whole industry. This book by an expert insider, fills this gap with a comprehensive review of history and evolution, new technologies and the future of exchanges.

Contains some, or all, of the following: highlights, notes, and underlining. Dog earred pages. Open Books is a nonprofit social venture that provides literacy experiences for thousands of readers each year through inspiring programs and creative capitalization of books.

A fresh look at the ever-changing world of mutual funds Like all investment instruments, mutual funds continue to evolve. In the last decade however, there has been plenty of change, including market capitalization, the introduction of new types of funds, and the expansion of the mutual fund model to include investments in commodities. Getting Started in Mutual Funds, Second Edition offers a completely updated look at this popular investment vehicle, including everything from Morningstar's new matrix of evaluating a fund's investment style to implementing mutual funds into long-term investment strategies in retirement plans. Throughout the book, author Alvin Hall also focuses on the basics, like how to read a prospectus, how to evaluate ongoing fees and expenses, and how to gauge a fund's performance. Acquaints you with the various types of mutual funds and how they are structured Explains important mutual fund terms and concepts New chapters include information on exchange-traded funds and how they compare to mutual funds in terms of performance, risk and fees Reveals how to assess a fund manager's investment style and its impact on your returns Gain a better understanding of mutual funds and maximize your investment returns with Getting Started in Mutual Funds, Second Edition.

Second Generation Cell and Gene-Based Therapies: Biological Advances, Clinical Outcomes, and Strategies for Capitalization serves as the only book on the market to bridge basic science, clinical therapy, technology development and business in the field of cellular therapy/cytotherapy. After more than two decades of painstaking fundamental research, the concept of therapeutic cells (stem cells, genes, etc.), beyond the concept of vaccines is reaching clinical trial, with mounting confidence in the safety and efficacy of these products. Nonetheless, numerous incremental technical advances remain to be achieved. Thus, this volume highlights the possible R&D paths that will ultimately facilitate clinical delivery of cutting-edge, curative products. Chapters cover hematopoietic stem cells, mesenchymal stem cells, tissue engineering, CAR-T cells, and cells of the immune system, as well as enabling technologies, such as gene and genome editing. Additionally, deep dives in product fundamentals, the history of the science, the pathobiology of diseases, the scientific and technological bases, and financing and technology adoption constraints are taken in order to unravel what will shape the cytotherapy industry in 2025 and beyond. Helps readers learn about the most current trends in cell-based therapy, their overall effectiveness from a clinical prospective, and how the industry is moving therapies forward for capitalizationPerspectives section at the end of each chapter summarizes key learnings, hypotheses, and objectives highlighted Edited and authored by scientists representing both basic and clinical research and industry, presenting a complete story of the current state and future promise of cellular therapies

Applied Equity Valuation provides comprehensive coverage of the theory and practice of all aspects of valuation, including security valuation in a complex market, bottom-up approach to small capitalization active management, top down/thematic equity management, implementing an integrated quantitative investment process, applying the DDM, value-based equity strategies, market-neutral portfolio management, enhanced indexing, dynamic style allocation, and exploiting global equity pricing anomalies.

Second Generation Cell and Gene-Based Therapies: Biological Advances, Clinical Outcomes, and Strategies for Capitalization serves as the only book on the market to bridge basic science, clinical therapy, technology development and business in the field of cellular therapy/cytotherapy. After more than two decades of painstaking fundamental research, the concept of therapeutic cells (stem cells, genes, etc.), beyond the concept of vaccines is reaching clinical trial, with mounting confidence in the safety and efficacy of these products. Nonetheless, numerous incremental technical advances remain to be achieved. Thus, this volume highlights the possible R&D paths that will ultimately facilitate clinical delivery of cutting-edge, curative products. Chapters cover hematopoietic stem cells, mesenchymal stem cells, tissue engineering, CAR-T cells, and cells of the immune system, as well as enabling technologies, such as gene and genome editing. Additionally, deep dives in product fundamentals, the history of the science, the pathobiology of diseases, the scientific and technological bases, and financing and technology adoption constraints are taken in order to unravel what will shape the cytotherapy industry in 2025 and beyond. Helps readers learn about the most current trends in cell-based therapy, their overall effectiveness from a clinical prospective, and how the industry is moving therapies forward for capitalizationPerspectives section at the end of each chapter summarizes key learnings, hypotheses, and objectives highlighted Edited and authored by scientists representing both basic and clinical research and industry, presenting a complete story of the current state and future promise of cellular therapies

Hewlett Packard is an American icon, the largest information technology company in the world. The bedrock of Silicon Valley, it employs more than 300,000 people, its market capitalization is in excess of 100 billion and its products are in almost every home in the country where there is a printer or computer. In 2003 the company began a transition from the family management style of its founders. It made a bold statement by hiring as its new CEO the most visible female business executive in America: Carly Fiorina. Less than two years later, the board fired her, amid accusations of imperiousness that had begun damagingly to leak into the business media. The board at that time included one of Silicon Valley’s most flamboyant venture capitalists and owner of the largest and most expensive yacht in the world, and a former CIA asset who believed he personally channeled the values of the company’s founders. Each had a long and complicated history with HP, and each believed he should determine the company’s future. They ran up against a corporate governance expert whom they could not roll, and a new CEO whose loyalties on the board were entirely opaque. In this way, the stage was set for a rancorous feud that split the board into implacably distrusting factions. In the middle of the damaging schism, HP introduced the Big Lie. The lie was pinned on the chairman, who was receiving treatment for stage 4 ovarian cancer. And it sizzled through a largely unquestioning media. Anthony Bianco gets to heart of the ethical morass at HP that ended up damning the entire board that created it. Almost every American has an interest in how the country’s greatest corporations are run, and the character of the people entrusted with them. The story of Hewlett-Packard reflects power struggles that shape corporate America and is an alarming morality tale for our times.

Since 1981, over 100 governments around the world have raised over $1 trillion through the sale of SOEs to private investors. Privatization programs have transformed the role of the state in virtually all-major economies, and have massively increased the capitalization and liquidity of all non-U.S. stock markets. The focus of this book lies on where privatization stands today and what are the next frontiers, the why and how behind countries who privatize certain industries, whether privatization works as an economic tool and important insights relevant to financial institutions such as how to value privatized industries, how share offerings differ from private offerings, and how countries go about harnessing private capital. The book will also represent a key and unique source for information related to the details of asset sales privatization, a summary of statistics of privatized companies from 54 international stock exchanges, regulatory changes and sources for privatization information for investors, government officials, bankers and financial specialists. The volume will serve as an invaluable reference for professionals and as a core or supplementary text in privatization courses.